ATRX and central nervous system cancer: The incidence of pathogenic TP53 alterations was investigated across our cohort and were present in 46% (212/463) of all samples; while alterations in ATRX and pTERT were present in 26% (120/463) and 53% (245/463) of all glioma samples, respectively.